Zusammenfassung
Viele Arzneimittel können aufgrund ihrer geringen Wasserlöslichkeit nicht über die Nieren eliminiert werden. Sie unterliegen daher einem Metabolismus, der zu wasserlöslichen Stoffwechselprodukten führt. Im Mittelpunkt dieses Stoffwechsels, der überwiegend in der Leber stattfindet, steht das Cytochrom P-450, durch das Arzneimittel oxidativ verändert werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aarts EM (1985) Evidence for the function of D-glucaric acid as indicator for the drug induced enhanced metabolism through the glucuronic acid pathway in man. Biochem Pharmacol 14: 359–363
Alvan G, Piafski K, Lind M, von Bahr C (1977) Effect of pentobarbital on the disposition of alprenolol. Clin Pharmacol Ther 22: 316–321
Baldeo WC, Gilbert JN, Powell JW (1980) Multidose studies in the human metabolism of pentobarbitone. Eur J Drug Metab Pharmacokinet 5: 75–80
Bayliff CD, Schwartz ML, Hardy BG (1985) Pharmacokinetics of high-dose pentobarbital in severe head trauma. Clin Pharmacol Ther 38: 457–461
Berman ML, Green OC (1971) Acute stimulation of Cortisol metabolism by pentobarbital in man. Anesthesiology 34: 365–369
Breimer DD, Honhoff C, Zilly W, Richter E, van Rossum JM (1975) Pharmacokinetics of hexo- barbital in plasma of man after intravenous infusion. J Pharmacokin Biopharm 3: 1–11
Breimer DD, Zilly W, Richter E (1976) Influence of rifampicin on drug metabolism: Differences between hexobarbital and antipyrine. Clin Pharmacol Ther 21: 470–480
Brown MW, Maldonado AL, Meredith AL, Meredith CG, Speeg KV (1985) Effect of keto- conazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther 37: 290–297
Campos AR, Herraez FXV, Marcos RJ, Amer JG, Porcar RC, Lucia PI (1980) Drug use in an intensive care unit and its relation to survival. Intens Care Med 6: 163–168
Chalk JB, Ridgeway JB, Brophy T, Yelland JDN, Eadie MJ (1984) Phenytoin impairs the bio¬availability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psych 47: 1087–1090
Collste P, Seideman P, Borg K-O, Haglund K, von Bahr C (1979) Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol. Clin Pharmacol Ther 25: 423–424
Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19: 317–366
Danhof M, Verbeek RMA, Van Boxtel CJ, Boeijing JK, Breimer DD (1982) Differential effects of enzyme induction on antipyrine metabolite formation. Brit J Clin Pharmacol 13: 379–386
Ehrnebo M (1974) Pharmacokinetics and distribution of pentobarbital in humans following oral and intravenous administration. J Pharm Sei 6: 1114–1118
Freitag B, Borman T (1982) Arzneimittelinteraktionen in der Intensivtherapie. Anaesthesiol Reanim 7: 147–152
Gabrielsen J, Bendtsen A, Eriksen H, Andersen S (1985) Methylprednisolone halflife during simultaneous barbiturate treatment and mechanical hyperventilation in neurosurgical patients. J Neurosurg 62: 182–185
Gibson GA, Blouin RA, Bauer LA, Rapp RP, Tibbs PA (1985) Influence of high-dose pentobarbital on theophylline pharmacokinetics. A case report. Ther Drug Monitor 7: 181–184
Haglund K, Seideman P, Collste P, Borg K-O, von Bahr C (1979) Influence of pentobarbital on metoprolol plasma levels. Clin Pharmacol Ther 26: 326–329
Hansen JM, Siersbaeck-Nielsen K, Skovsted L (1971) Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 12: 539–544
Heinemeyer G, Roots I, Gramm HJ, Dennhardt R (1985) Induction and inhibition of drug elimination in critical care patients as shown by pentobarbital and metamizol clearance. Biochem Pharmacol 34: 413–414
Heinemeyer G, Roots I, Schulz H, Dennhardt R (1985) Hemmung der Pentobarbital-Elimination durch Miconazol bei Intensivtherapie des erhöhten intracraniellen Druckes. Intensivmed 22: 164–167
Heinemeyer G, Roots I, Lestau P, Klaiber H-R, Dennhardt R (1986) D-glucaric acid excretion in critical care patients — comparison to 6/3-hydroxyCortisol excretion and serum /-glutamyl- transpeptidase activity and relation to multiple drug therapy. Brit J Clin Pharmacol 21: 9–18
Heinemeyer G, Roots I, Dennhardt R (1986) Monitoring of pentobarbital plasma levels in critical care patients suffering from increased intracranial pressure. Ther Drug Monitor 8: 145–150
Heinemeyer G, Gramm H-J, Simgen W, Dennhardt R, Roots I (1987) Hexobarbital and di- pyrone kinetics in critical care patients receiving high-dose pentobarbital. Eur J Clin Pharmacol 32: 273–277
Heinemeyer G (1987) Clinical pharmacokinetic considerations in the treatment of raised intracranial pressure. Clin Pharmacokinet 13: 1–25
Hildebrandt AG, Roots I, Speck M, Saalfrank K, Kewitz H (1975) Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo. Eur J Clin Pharmacol 8: 327–336
Hildebrandt AG, Roots I, Heinemeyer G, Nigam S, Helge H (1978) Aminopyrine as one of the parameters to measure in vivo drug metabolism in man and animal. In: Estabrook RW, Linden-laub E (eds) The induction of drug metabolism. Schattauer Verlag, Stuttgart, New York, pp 615–627
Klotz U, Reimann I (1980) Delayed clearance of diazepam due to Cimetidine. N Engl J Med 301: 1012–1014
Kutt H, Winters W, McDowell FH (1966) Depression of parahydroxylation of diphenylhydantoin by antituberculosis therapy. Neurology 16: 594–602
Loft S, Sonne J, Pilsgaard H, Dossing M, Poulsen E (1986) Inhibition of antipyrine elimination by disulfiram and Cimetidine. The effect of concomitant administration. Brit J Clin Pharmacol 21: 75–77
Marselos M, Alakuijala P, Lang M, Törönen R (1977) Studies on the mechanism by which disulfiram and diethyldithiocarbamate affect drug metabolism. In: Ullrich V, Roots I, Hildebrandt AG, Estabrook RW, Conney AH (eds) Microsomes and drug oxidations. Pergamon Press, Oxford, pp 589–596
Neuvonen PJ, Penttilae O (1974) Interaction between doxycycline and barbiturates. Brit Med J 1: 535–536
Neuvonen PJ, Tokola RA, Kaste M (1981) Cimetidine - phenytoin interaction. Effect on serum Phenytoin concentration and antipyrine test. Eur J Clin Pharmacol 21: 215–220
Niemeegers CE, Levron JC1, Awouters F, Janssen PAJ (1982) Inhibition and induction of microsomal enzymes in the rat. A comparison of four antimycotics miconazole, econazole, clotrimazole and ketoconazole. Arch Int Pharmacodyn 251: 26–38
Ohnhaus EE, Park BK (1979) Measurement of urinary 6/K)HF excretion as an in vivo parameter on the clinical assessment of the microsomal enzyme — inducing capacity of antipyrine, pheno- barbitone and rifampicin. Eur J Clin Pharmacol 15: 139–145
Park BK (1982) Assessment of the drug metabolism activity of the liver. Brit J Clin Pharmacol 14: 631–651
Peden NR, Rewhorn I, Champion MC, Mussani R, Ooi TC (1984) Cortisol and dexamethasone elimination during treatment with Cimetidine. Brit J Clin Pharmacol 18: 101–103
Perucca E, Hedges A, Makki KA, Rutprah M, Wilson JF, Richens A (1985) A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Brit J Clin Pharmacol 18: 401–410
Pessayre D, Mazel P (1976) Induction and inhibition of hepatic drug metabolizing enzymes by rifampin. Biochem Pharmacol 25: 943–949
Rameis H (1985) Die Bedeutung des „Drug-Monitoring“für die Intensivmedizin. Intensivmed 21: 64–68
Reiche R, Frey H-H (1981) Interactions between chloramphenicol and intravenous anesthetics. Anästhesist 30: 504–507
Remmer H, Fleischmann R, Kunz W (1978) Pharmacological consequences of induction of drug metabolizing enzymes. In: Estabrook RW, Lindenlaub E (eds) The induction of drug metabolism. Schattauer Verlag, Stuttgart, New York, pp 556–581
Rietbrock I, Lazarus G, Richter E, Breimer DD (1981) Hexobarbitone disposition at different stages of intensive care treatment. Brit J Anaesth 53: 283–293
Roots I (1979) Effect of rifampicin on urinary excretion of 6/?-hydroxycortisol and glucaric acid in man and animal. Arch Pharmacol [Suppl R72] 307
Roots I, Ley B, Hildebrandt AG (1978) In vivo parameters of drug metabolism — Differences in specificity towards inducing agents. In: Ullrich V, Roots I, Hildebrandt AG, Estabrook RW, Conney AH (eds) Microsomes and drug oxidations. Pergamon Press, Oxford, pp 581–588
Roots I, Holbe R, Hövermann W, Nigam S, Heinemeyer G, Hildebrandt AG (1979) Quantitative determination by HPLC of urinary 6 ß-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol 16: 63–71
Roots I (1986) Wann ist die Bestimmung von Arzneimittelkonzentrationen im Plasma nützlich oder notwendig? Internist 27: 40–52
Rosalki SB, Tarlow D, Rau D (1971) Plasma gamma glutamyltranspeptidase elevation in patients receiving enzyme inducing drugs. Lancet 2: 376–377
Schaible DH, Cupit GC, Swedlow DB, Rocci ML Jr (1982) High-dose pentobarbital pharmacokinetics in hypothermic brain-injured children. J Pediatr 100: 655–660
Seideman P, Ericsson O, Groningsson K, Von Bahr C (1981) Effect of pentobarbital on the formation of diastereomeric oxazepam glucuronides in man. Analysis by high performance liquid chromatography. Acta Pharmacol Toxicol 49: 200–204
Skovsted L, Hansen JM, Kristensen M, Christensen LK (1974) Inhibition of drug metabolism in man. In: Morselli L, Garratini S, Cohen SN (eds) Drug interactions. Raven Press, New York, pp 81–90
Somogyi A, Gugler R (1982) Drug interactions with Cimetidine. Clin Pharmacokin 7: 23–41
Sotaniemi EA, Medzihradsky F, Eliasson G (1974) Glucaric acid as an indicator of use of enzyme inducing drugs. Clin Pharmacol Ther 15: 417–423
Vesell E, Passananti GT, Greene FE (1973) Impairment of drug metabolism in man by allopurinol and nortriptyline. New Engl J Med 283: 1484
Vesell ES, Passananti GT, Glenwright PA, Dvorchik BH (1975) Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin Pharmacol Ther 18: 259–272
Vesell ES (1979) The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther 26: 275–286
Vital Durand D, Hampden C, Boobis AR, Park BK, Davies DS (1986) Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long acting rifamycine derivative. Brit J Clin Pharmacol 21: 1–7
Vree TB, Henderson PT, van der Kleijn E, Guelen PMJ (1975) Drug interactions at the metabolic level. A reality in drug treatment of epilepsy. In: Schneider H, Janz D, Gardner-Thorpe C, Meinardi H, Sherwin AL (eds) Clinical pharmacology of antiepileptic drugs. Springer Verlag, New York, Heidelberg, Berlin, pp 34–42
Watson WA, Godley PJ, Garriott JC, Bradberry JC, Puckett JD (1983) Blood pentobarbital concentrations during thiopental therapy. Drug Intell. Clin. Pharm 20: 283–287
Werk EE, MacGee J, Sholiton J (1964) Altered Cortisol metabolism in advanced cancer and other terminal illness: excretion of 6ß-hydroxycortisol. Metabolism 13: 1425–1438
Wessling H, Mols-Türkow I (1975) Interaction between diphenylhydantoin ( DPH) and tolbutamide in man. Eur J Clin Pharmacol 8: 75–78
Whitfield JB, Moss DW, Neale G Orme, M Breckenridge A (1973) Changes in plasma-gamma- glutamyltranspeptidase activity associated with alterations in drug metabolism in man. Brit Med J 1: 316–318
Wong DD, Longenecker DG, Liepman M, Baker S, LaVergne M (1985) Phenytoin-dexametha- sone: A possible drug-drug interaction. JAMA 15: 2062–2063
Yamada S, Iwai K (1976) Induction of hepatic cortisol-6-hydroxylase by rifampicin. Lancet 2: 366–367
Zemaitis MA, Greene FE (1976) Impairment of hepatic microsomal and plasma esterases of the rat by disulfiram and diethyldithiocarbamate. Biochem Pharmacol 25: 453–459
Zilly W, Breimer DD, Richter E (1978) Hexobarbital disposition in compensated and decompensated cirrhosis of the liver. Clin Pharmacol Ther 23: 525–534
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Heinemeyer, G. (1988). Hemmung und Induktion des Arzneimittelstoffwechsels bei Intensivpatienten. In: Aspekte der Arzneitherapie bei Intensivpatienten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71694-2_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-71694-2_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17261-1
Online ISBN: 978-3-642-71694-2
eBook Packages: Springer Book Archive